Trident Lifeline IPO Details & Guidance

Grey Market News for Trident Lifeline IPO #
On 10 October 2022, click

Trident Lifeline IPO Subscription Status
On 29 September 2022 @ 5.00 pm
NII 50%  16,62,200 Shares: 1.69T
RII 50%  16,62,200 Shares: 0.98T
Total     33,24,000 Shares: 1.34T

Trident Lifeline IPO Details
IPO Dates   26-09-2022 to 29-9-2022
Face Value  Rs 10 per share
IPO Price    Rs 101 per share
Lot             1,200 Shares
Issue Size  34,99,200 shares of Rs 10
Issue           Rs 35.34 Cr)
# Fresh Issue 34,99,200 shares of Rs 10/Rs 35.34 Cr
# Offer for Sale – shares of Rs 10/ Rs – Cr
Issue Type Book Built IPO
Listing At BSE SME
Objects of the IPO
1. To meet the working capital requirements
2. Product registration in the international markets

Retail Offer: 50 % / 16,62,200 Shares
RII Min. Application: 1,200 Shares, Rs. 1,21,200
RII Max. Application: 1,200 Shares, Rs. 1,21,200
1385 Applications required for onetime RII-subscriptions.

Trident Lifeline IPO Timetable 
IPO Opening Date: September 26, 2022
IPO Closing Date: September 29, 2022
Basis of Allotment: October 04, 2022
Initiation of Refunds: October 06, 2022
Credit of Shares to Demat A/cs: October 07, 2022
IPO Listing Date: October 10, 2022

Trident Lifeline Business:
The Company is engaged in the pharmaceutical business ethical marketing in domestic as well as inernational market. It is also engaged in distribution of pharmaceutical products through third party distribution network. It offers wide range of pharmaceutical formulations and products manufactured on contract manufacturing under loan lisence. It operates in India as well as African, Latin American and East Indian Countries. It has its presence through registered products or products under registration in countries like Bolivia, Cambodia, Cameroon, Chile, Ghana, Kenya, Myanamar, Nigeria, Peru, Sudan, Tajikistan, Uzbekistan, Venuzela.

It deals in Capsules, Tablets, Liquid Ointment, Gel, Ice Gel, Mouthwash, Paste, Solution, Suspension, Drypowders and Toothpaste. Its product portfolio comprises of vide range of drugs like Anti Bacterial, Anti Diarrheal, Anti Fungal, Anti Malerial, Anti Diabetic, Dental Cure, Proton Pump Inhibitor, Anti Protozol, Anti Histamine, Anti Hypertensive drugs, Anti Lipidemic Drug, Anti Parasitic, Multivitamin, Multimineral Nyteraceutical and Non-steriodal anti-inflamatory drug (NSAIDS). Its product portfolio consists of 832 products, as on May 31, 2022. It operates under different brand names across the globe. As on May 31, 2022, it has 267 products registered in total 8 countries. As on May 31, 2022, total 565 products are under process of registration in 11 countries, which shall boost the growth of the company.
For more information about the company, Click Website: www.tridentlifeline.com

Business Summary: 
Promoters of Trident Lifeline
MR. HARDIK JIGISHKUMAR DESAI, MR. MAYURKUMAR MANSUKHBHAI GAJERA, MRS. RUPABEN C
JARIWALA, MRS. RINKAL MAYURBHAI GAJERA, MR. TARANG NATHABHAI GAJERA, MR. MOHAK NATHABHAI GAJERA

Registered office of Trident Lifeline
2nd Floor, Shop-2004, North Extension, Falsawadi Begumpura, Nodh-4/1650, Sahara Darwaja, Surat – 395003, Gujarat, India
Company Secretary and Compliance Officer: Mr. Kunal Amrishbhai Chauhan

Lead Manager of Trident Lifeline
Beeline Capital Advisors Private Limited
Registrar to the IPO of Trident Lifeline
Link Intime India Private Limited

SME IPO Financial & Analytical Ratios#
Total Income 2019-20             Rs 5.01 Cr
Total Income 2020-21             Rs 9.78 Cr
Total Income 2021-22             Rs 22.37 Cr
Net Profit 2019-20                  Rs (0.80) Cr
Net Profit 2020-21                  Rs 0.63 Cr
Net Profit 2021-22                  Rs 2.24 Cr
Earnings per Share 2019-20   Rs (3.12)
Earnings per Share 2020-21   Rs 1.53
Earnings per Share 2021-22   Rs 3.98
Return on Net Worth: 19-20: – %
Return on Net Worth: 20-21: – %
Return on Net Worth: 21-22: 46.79 % 
Book Value of the Share as on 31.03.22 Rs 6.07
NAV after the IPO Rs. –
Offer Price Rs. 101

IPO Peer Comparison:
Vaishali Pharma @ PE Ratio of 20.92
Chandra bhagat Pharma @ PE Ratio of 82.97

Observation by Paresh Gordhandas (Research Analyst)

Will be updated soon

# This is only coverage of News related to Grey Market. We do not deal in grey market premium or Subject to rates, nor we recommend dealing in Grey Market. Investment decision based on Grey Market trends can be faulty.